<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04912609</url>
  </required_header>
  <id_info>
    <org_study_id>3AL-SPG11</org_study_id>
    <nct_id>NCT04912609</nct_id>
  </id_info>
  <brief_title>Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)</brief_title>
  <acronym>3AL-SPG11</acronym>
  <official_title>An Observational Study in Subjects With Spastic Paraplegia Type 11 Taking Trehalose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Fondazione Stella Maris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Fondazione Stella Maris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that&#xD;
      produces spatacsin, a protein involved in lysosomal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several experiments on subjects affected by neurodegenerative diseases with dysfunction of&#xD;
      the autophagic-lysosomal system show that trehalose improves the pathological phenotype. This&#xD;
      evidence indicates that trehalose could be used in patients with SPG11 to try to prevent the&#xD;
      accumulation of glycosphingolipids at the lysosomal level and induce the genesis of new&#xD;
      lysosomes. This study aims to record clinical data of 20 patients with SPG11 who take&#xD;
      trehalose during 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in Spastic Paraplegia Rating Scale (SPRS) at 6 and 12 months</measure>
    <time_frame>At baseline, month 6, month 12</time_frame>
    <description>Assess changes in score of the Spastic Paraplegia Rating Scale (SPRS) over ± 10%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glycosphingolipids and gangliosides plasmatic levels</measure>
    <time_frame>At baseline, month 6, month 12</time_frame>
    <description>Assess changes in glycosphingolipids and gangliosides plasmatic levels over ± 10%</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hereditary Spastic Paraplegia</condition>
  <condition>Spastic Paraplegia Type 11</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be enrolled in our centre (IRCCS Fondazione Stella Maris) as part of the&#xD;
        primary care during regular visits.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of SPG11&#xD;
&#xD;
          -  Written signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of other concomitant neurodegenerative diseases&#xD;
&#xD;
          -  taking other experimental drugs within 30 days of the first Study visit (T0) and&#xD;
             during the study&#xD;
&#xD;
          -  Refusal to sign informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo M Santorelli, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Filippo Santorelli-Lab Med Molecolare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo M Santorelli, MD PhD</last_name>
    <phone>0039050886231</phone>
    <email>filippo3364@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucrecia A Mota, D.M.L</last_name>
    <phone>+39050992140</phone>
    <email>lucreciaantonia.mota@fsm.unipi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS Fondazione Stella Maris</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Boutry M, Branchu J, Lustremant C, Pujol C, Pernelle J, Matusiak R, Seyer A, Poirel M, Chu-Van E, Pierga A, Dobrenis K, Puech JP, Caillaud C, Durr A, Brice A, Colsch B, Mochel F, El Hachimi KH, Stevanin G, Darios F. Inhibition of Lysosome Membrane Recycling Causes Accumulation of Gangliosides that Contribute to Neurodegeneration. Cell Rep. 2018 Jun 26;23(13):3813-3826. doi: 10.1016/j.celrep.2018.05.098.</citation>
    <PMID>29949766</PMID>
  </reference>
  <reference>
    <citation>Branchu J, Boutry M, Sourd L, Depp M, Leone C, Corriger A, Vallucci M, Esteves T, Matusiak R, Dumont M, Muriel MP, Santorelli FM, Brice A, El Hachimi KH, Stevanin G, Darios F. Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration. Neurobiol Dis. 2017 Jun;102:21-37. doi: 10.1016/j.nbd.2017.02.007. Epub 2017 Feb 22.</citation>
    <PMID>28237315</PMID>
  </reference>
  <reference>
    <citation>Chang J, Lee S, Blackstone C. Spastic paraplegia proteins spastizin and spatacsin mediate autophagic lysosome reformation. J Clin Invest. 2014 Dec;124(12):5249-62. doi: 10.1172/JCI77598. Epub 2014 Nov 3.</citation>
    <PMID>25365221</PMID>
  </reference>
  <reference>
    <citation>de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN, Bortholin T, Oliveira ASB. Hereditary Spastic Paraplegia: Clinical and Genetic Hallmarks. Cerebellum. 2017 Apr;16(2):525-551. doi: 10.1007/s12311-016-0803-z. Review.</citation>
    <PMID>27271711</PMID>
  </reference>
  <reference>
    <citation>Davies JE, Sarkar S, Rubinsztein DC. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet. 2006 Jan 1;15(1):23-31. Epub 2005 Nov 25.</citation>
    <PMID>16311254</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Fondazione Stella Maris</investigator_affiliation>
    <investigator_full_name>Filippo Maria Santorelli</investigator_full_name>
    <investigator_title>Director Molecular Medicine, Neurogenetics and Neuromuscular Disorders</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Spasticity</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Spastic Paraplegia, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

